Point-of-Care Testing in Coagulation

Clinics in Laboratory Medicine

Volumn 29, Issue 3, 2009, Pages 543-553

  Van Cott, Elizabeth M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Activated clotting time; D dimer; Platelet function testing; PT INR

Indexed keywords

ACETYLSALICYLIC ACID; APROTININ; ARGATROBAN; CLOPIDOGREL; CREATINE KINASE MB; D DIMER; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OMEPRAZOLE; PAROXETINE; THROMBIN INHIBITOR; TROPONIN I; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; DRUG MONITORING; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SELF EVALUATION; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

BLOOD COAGULATION TESTS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS;

EID: 70349962904     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.06.016     Document Type: Review

References (60)

1. Gardiner C., Mackie S., and Mackie I. Point-of-care testing in hemostasis. In: Kitchen S., Olson J., and Preston F.E. (Eds). Quality in laboratory hemostasis and thrombosis (2009), Wiley-Blackwell, Hoboken (NJ) 72-80
2. Paniccia R., Antonucci E., Gori A.M., et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 128 1 (2007) 143-149
3. Hayward C.P., Harrison P., Cattaneo M., et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4 2 (2006) 312-319
4. Schlammadinger A., Kerenyi A., Muszbek L., et al. Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease. Thromb Haemost 84 1 (2000) 88-92
5. Campo G., Valgimigli M., Frangione A., et al. Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. J Thromb Haemost 6 10 (2008) 1824-1826
6. Michelson A.D., Cattaneo M., Eikelboom J.W., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 6 (2005) 1309-1311
7. Patrono C., Baigent C., Hirsh J., et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 6 Suppl (2008) 199S-233S
8. Douketis J.D., Berger P.B., Dunn A.S., et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 6 Suppl (2008) 299S-339S
9. Campbell C.L., Smyth S., Montalescot G., et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297 18 (2007) 2018-2024
10. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 6 (2003) 961-965
11. Bliden K.P., DiChiara J., Tantry U.S., et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 6 (2007) 657-666
12. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 24 (2007) 2312-2317
13. Chen W.H., Cheng X., Lee P.Y., et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 120 7 (2007) 631-635
14. Buch A.N., Singh S., Roy P., et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 99 11 (2007) 1518-1522
15. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 8 (2008) 992-1000
16. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119 2 (2009) 237-242
17. Patti G., Nusca A., Mangiacapra F., et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity predicts Outcome) study. J Am Coll Cardiol 52 14 (2008) 1128-1133
18. Gianetti J., Parri M.S., Sbrana S., et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res 118 4 (2006) 487-493
19. Marcucci R., Paniccia R., Antonucci E., et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 98 9 (2006) 1156-1159
20. Andersen K., Hurlen M., Arnesen H., et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 1 (2002) 37-42
21. Pamukcu B., Oflaz H., Onur I., et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 18 2 (2007) 187-192
22. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 4 (2009) 354-362
23. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 4 (2009) 363-375
24. Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 9 (2009) 937-944
25. Juurlink D.N., Gomes T., Ko D.T., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180 7 (2009) 713-718
26. Freedman J.E., and Hylek E.M. Clopidogrel, genetics, and drug responsiveness. N Engl J Med 360 4 (2009) 411-413
27. Poller L., Keown M., Ibrahim S.A., et al. Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment. Clin Chem 52 10 (2006) 1843-1847
28. Christensen T.D., Larsen T.B., Jensen C., et al. International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy. Thromb Haemost 101 3 (2009) 563-569
29. Karon B.S., McBane R.D., Chaudhry R., et al. Accuracy of capillary whole blood international normalized ratio on the CoaguChek S, CoaguChek XS, and i-STAT 1 point-of-care analyzers. Am J Clin Pathol 130 1 (2008) 88-92
30. Siebenhofer A., Rakovac I., Kleespies C., et al. Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial. Thromb Haemost 100 6 (2008) 1089-1098
31. Deom A., Reber G., Tsakiris D.A., et al. Evaluation of the CoaguChek XS Plus system in a Swiss community setting. Thromb Haemost 101 5 (2009) 988-990
32. Torreiro E.G., Fernandez E.G., Rodriguez R.M., et al. Comparative study of accuracy and clinical agreement of the CoaguChek XS portable device versus standard laboratory practice in unexperienced patients. Thromb Haemost 101 5 (2009) 969-974
33. Heneghan C., Alonso-Coello P., Garcia-Alamino J.M., et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 367 9508 (2006) 404-411
34. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 6 Suppl (2008) 160S-198S
35. Anderson D.R., Harrison L., and Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. Arch Intern Med 153 12 (1993) 1441-1447
36. van den Besselar A.M. A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin. Thromb Haemost 84 3 (2000) 410-412
37. Perry S.L., Samsa G.P., and Ortel T.L. Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. Thromb Haemost 94 6 (2005) 1196-1202
38. van den Besselaar A.M., Witteveen E., and van der Meer F.J. Influence of haematocrit on international normalised ratio (INR) differences between a whole blood point-of-care coagulation monitor and reference prothrombin time in plasma. Thromb Haemost 100 6 (2008) 1181-1184
39. Heim S.W., Schectman J.M., Siadaty M.S., et al. D-dimer testing for deep venous thrombosis: a metaanalysis. Clin Chem 50 7 (2004) 1136-1147
40. Reber G., de Moerloose P., Coquoz C., et al. Comparison of two rapid D-dimer assays for the exclusion of venous thromboembolism. Blood Coagul Fibrinolysis 9 4 (1998) 387-388
41. Kline J.A., Israel E.G., Michelson E.A., et al. Diagnostic accuracy of a bedside D-dimer assay and alveolar dead-space measurement for rapid exclusion of pulmonary embolism: a multicenter study. JAMA 285 6 (2001) 761-768
42. Ghys T., Achtergael W., Verschraegen I., et al. Diagnostic accuracy of the Triage D-dimer test for exclusion of venous thromboembolism in outpatients. Thromb Res 121 6 (2008) 735-741
43. ® D-dimer exclusion test: validation and utility for use in the central laboratory and at the point of care. Point of Care 4 (2005) 133-137
44. La'ulu S.L., Dominguez C.M., and Roberts W.L. Performance characteristics of the AxSYM D-dimer assay. Clin Chim Acta 390 1-2 (2008) 148-151
45. Lee-Lewandrowski E, Nichols J, VanCott EM, et al. Implementation of a rapid whole blood D-dimer test in the emergency department of an urban academic medical center: impact on ED length of stay and ancillary test utilization. Am J Clin Pathol, in press.
46. Freyburger G., Reboul M.P., Labrouche S., et al. Diagnosis accuracy of a new challenger for thrombosis exclusion, the Stratus CS DDMR. Clin Chim Acta 354 1-2 (2005) 181-189
47. Reber G., Bounameaux H., Perrier A., et al. A new rapid point-of-care D-dimer enzyme-linked immunosorbent assay (Stratus CS D-dimer) for the exclusion of venous thromboembolism. Blood Coagul Fibrinolysis 15 5 (2004) 435-438
48. Shitrit D., Heyd J., Raveh D., et al. Diagnostic value of the D-dimer test in deep vein thrombosis: improved results by a new assay method and by using discriminate levels. Thromb Res 102 2 (2001) 125-131
49. Shitrit D., Levi H., Huerta M., et al. Appropriate indications for venous duplex scanning based on D-dimer assay. Ann Vasc Surg 16 3 (2002) 304-308
50. Gosselin R.C., Owings J.T., Kehoe J., et al. Comparison of six D-dimer methods in patients suspected of deep vein thrombosis. Blood Coagul Fibrinolysis 14 6 (2003) 545-550
51. Schutgens R.E., Haas F.J., Gerritsen W.B., et al. The usefulness of five D-dimer assays in the exclusion of deep venous thrombosis. J Thromb Haemost 1 5 (2003) 976-981
52. Gardiner C., Pennaneac'h C., Walford C., et al. An evaluation of rapid D-dimer assays for the exclusion of deep vein thrombosis. Br J Haematol 128 6 (2005) 842-848
53. Bucek R.A., Quehenberger P., Feliks I., et al. Results of a new rapid d-dimer assay (cardiac d-dimer) in the diagnosis of deep vein thrombosis. Thromb Res 103 1 (2001) 17-23
54. Dempfle C.E., Korte W., Schwab M., et al. Sensitivity and specificity of a quantitative point of care D-dimer assay using heparinized whole blood, in patients with clinically suspected deep vein thrombosis. Thromb Haemost 96 1 (2006) 79-83
55. Legnani C., Fariselli S., Cini M., et al. A new rapid bedside assay for quantitative testing of D-dimer (Cardiac D-Dimer) in the diagnostic work-up for deep vein thrombosis. Thromb Res 111 3 (2003) 149-153
56. Arpino P.A., Cronin-Jenkins S., Misiano D., et al. Comparing the activated clotting times obtained from 2 point-of-care devices in patients receiving unfractionated heparin during percutaneous coronary intervention. Point of Care 7 (2008) 30-33
57. Chia S., Van Cott E.M., Raffel O.C., et al. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Thromb Haemost 101 3 (2009) 535-540
58. Kratz A., and Van Cott E.M. Activated clotting time: methods and clinical applications. Point of Care 4 (2005) 90-94
59. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 4 (2006) 353-365
60. Mangano D.T., Miao Y., Vuylsteke A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 297 5 (2007) 471-479